Valganciclovir HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 558287

CAS#: 175865-59-5 (HCl)

Description: Valganciclovir is an L-valyl ester (prodrug) of ganciclovir that exists as a mixture of two diastereomers. After oral administration, both diastereomers are rapidly converted to ganciclovir by intestinal and hepatic esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, which inhibits replication of human CMV in cell culture and in vivo. The reported EC50 values of ganciclovir that inhibit human CMV replication in cell culture (laboratory and clinical isolates) have ranged from 0.08 to 22.94 μM (0.02 to 5.75 mcg/mL).

Chemical Structure

Valganciclovir HCl
CAS# 175865-59-5 (HCl)

Theoretical Analysis

MedKoo Cat#: 558287
Name: Valganciclovir HCl
CAS#: 175865-59-5 (HCl)
Chemical Formula: C14H23ClN6O5
Exact Mass:
Molecular Weight: 390.825
Elemental Analysis: C, 43.03; H, 5.93; Cl, 9.07; N, 21.50; O, 20.47

Price and Availability

Size Price Availability Quantity
25.0mg USD 250.0 2 Weeks
50.0mg USD 450.0 2 Weeks
100.0mg USD 750.0 2 Weeks
Bulk inquiry

Related CAS #: 175865-59-5 (HCl)   175865-60-8 (free base)    

Synonym: RS 079070-194, RO 107-9070/194, RS-79070-194, RS-079070-194, ganciclovir L-valyl ester, Valganciclovir HCl, Cymeval, Valcyt, Valixa, Darilin, Rovalcyte, Patheon

IUPAC/Chemical Name: [2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate hydrochloride


InChi Code: InChI=1S/C14H22N6O5.ClH/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22;/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22);1H/t8?,9-;/m0./s1


Appearance: White to light yellow solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 390.825 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Vaziri S, Pezhman Z, Sayyad B, Mansouri F, Janbakhsh A, Afsharian M, Najafi F. Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis. J Res Med Sci. 2014 Dec;19(12):1185-92. Review. PubMed PMID: 25709661; PubMed Central PMCID: PMC4333528.

2: Stockmann C, Roberts JK, Knackstedt ED, Spigarelli MG, Sherwin CM. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):205-19. doi: 10.1517/17425255.2015.988139. Epub 2014 Nov 27. Review. PubMed PMID: 25428442.

3: Komatsu TE, Pikis A, Naeger LK, Harrington PR. Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways. Antiviral Res. 2014 Jan;101:12-25. doi: 10.1016/j.antiviral.2013.10.011. Epub 2013 Oct 31. Review. PubMed PMID: 24184129.

4: Kawalec P, Szkultecka-Debek M, Maks J, Paszulewicz A, Kaweczyńska-Lasoń A, Pilc A. [Clinical efficacy and safety of prolonged use of the valganciclovir for the treatment of cytomegalovirus disease in patients after kidney transplantation]. Pol Merkur Lekarski. 2013 Jul;35(205):10-3. Review. Polish. PubMed PMID: 23984598.

5: Yu MA, Park JM. Valganciclovir: therapeutic role in pediatric solid organ transplant recipients. Expert Opin Pharmacother. 2013 Apr;14(6):807-15. doi: 10.1517/14656566.2013.778244. Epub 2013 Mar 8. Review. PubMed PMID: 23469871.

6: Stronati M, Lombardi G, Garofoli F, Villani P, Regazzi M. Pharmacokinetics, pharmacodynamics and clinical use of valganciclovir in newborns with symptomatic congenital cytomegalovirus infection. Curr Drug Metab. 2013 Feb;14(2):208-15. Review. PubMed PMID: 22935067.

7: Kalil AC, Mindru C, Botha JF, Grant WJ, Mercer DF, Olivera MA, McCartan MA, McCashland TM, Langnas AN, Florescu DF. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis. Liver Transpl. 2012 Dec;18(12):1440-7. doi: 10.1002/lt.23530. Review. PubMed PMID: 22887929.

8: Chawla JS, Ghobadi A, Mosley J 3rd, Verkruyse L, Trinkaus K, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Westervelt P, DiPersio JF, Vij R. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. Transpl Infect Dis. 2012 Jun;14(3):259-67. doi: 10.1111/j.1399-3062.2011.00689.x. Epub 2011 Oct 28. Review. PubMed PMID: 22093134.

9: Manuel O, Perrottet N, Pascual M. Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation. Expert Rev Anti Infect Ther. 2011 Nov;9(11):955-65. doi: 10.1586/eri.11.116. Review. PubMed PMID: 22029513.

10: Pescovitz MD. Valganciclovir: recent progress. Am J Transplant. 2010 Jun;10(6):1359-64. doi: 10.1111/j.1600-6143.2010.03112.x. Epub 2010 Mar 28. Review. PubMed PMID: 20455881.

11: Asberg A, Rollag H, Hartmann A. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients. Expert Opin Pharmacother. 2010 May;11(7):1159-66. doi: 10.1517/14656561003742954. Review. PubMed PMID: 20367273.

12: Perrottet N, Decosterd LA, Meylan P, Pascual M, Biollaz J, Buclin T. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin Pharmacokinet. 2009;48(6):399-418. doi: 10.2165/00003088-200948060-00006. Review. PubMed PMID: 19650679.

13: Fernández-Ruiz M, Muñoz-Codoceo C, López-Medrano F, Faré-García R, Carbonell-Porras A, Garfia-Castillo C, Muñoz-Gómez R, Aguado-García JM. Cytomegalovirus myopericarditis and hepatitis in an immunocompetent adult: successful treatment with oral valganciclovir. Intern Med. 2008;47(22):1963-6. Epub 2008 Nov 17. Review. PubMed PMID: 19015608.

14: Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant. 2008 Oct;8(10):2111-8. doi: 10.1111/j.1600-6143.2008.02369.x. Review. PubMed PMID: 18828771.

15: Cvetković RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs. 2005;65(6):859-78. Review. PubMed PMID: 15819597.

16: Couzigou C, Mazeron MC, Escaut L, Merad M, Vittecoq D. [Valganciclovir maintenance therapy in AIDS: treatment failure due to the development of cytomegalovirus resistance to ganciclovir]. Med Mal Infect. 2005 Feb;35(2):98-100. Review. French. PubMed PMID: 15780901.

17: Razonable RR, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev Anti Infect Ther. 2004 Feb;2(1):27-41. Review. PubMed PMID: 15482169.

18: Freeman RB. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host. Expert Opin Pharmacother. 2004 Sep;5(9):2007-16. Review. PubMed PMID: 15330737.

19: Kroes AC. [Valganciclovir. Oral treatment of Cytomegalovirus infections]. Ned Tijdschr Geneeskd. 2004 Jun 19;148(25):1236-8. Review. Dutch. PubMed PMID: 15301386.

20: Weiskittel P. Valganciclovir hydrochloride (Valcyte): a new antiviral agent. Nephrol Nurs J. 2003 Feb;30(1):93-5. Review. PubMed PMID: 12674959.